Cybin Corp., an exemplary Canada-based life-science company focused on the development of pharmaceutical-grade psilocybin products, appears ideally positioned to leverage a milestone moment. Canada’s Minister of Health, the Honourable Patty Hajdu, recently approved the use of psilocybin therapy in the end-of-life treatment of four Canadians battling incurable cancer (http://nnw.fm/JVZYJ), and this groundbreaking decision bodes well … Continue reading “NetworkNewsBreaks – Cybin Corp. Poised Amid Groundbreaking Decision to Allow Psilocybin Therapy”
Cybin Corp. recently announced its entry into a feasibility agreement with IntelGenx Corp., a leading drug-delivery company focused on the development and manufacturing of pharmaceutical delivery films (http://nnw.fm/2F3bX). Under the agreement, the two companies will collaborate to develop an orally dissolving, fast-acting film for the delivery of pharmaceutical-grade psilocybin. A recent article discussing this quotes … Continue reading “NetworkNewsBreaks – Cybin Corp. Partners with IntelGenx to Develop Efficient Delivery Method for Pharmaceutical-Grade Psilocybin”
Canada’s Minister of Health approves the use of psilocybin therapy in end-of-life care of four Canadians battling incurable cancer The Decision marks first legal, medical exemptions for psilocybin use in Canada since the compound became illegal in 1974 Cybin subsidiary Serenity Life Sciences focuses on advancing R&D of psilocybin-based pharmaceutical products A ground-breaking decision by … Continue reading “Cybin Corp. Ideally Positioned as Landmark Decision Regarding Psilocybin Therapy Could Spark Increased Interest, Use”
Agreement with leading drug-delivery company outlines plans to develop fast-acting, orally dissolving film for delivery of pharmaceutical-grade psilocybin Cybin CEO notes that systemic bioavailability of film is projected to be high Cybin focused on developing fungi-derived psychedelic, medicinal products to treat mental illness, other health conditions Cybin Corp. announced that it has entered into a … Continue reading “Cybin Corp. Enters Feasibility Agreement to Develop Fast-Acting Psilocybin Film”
Cybin Corp., Canada’s leading-edge mushroom life-sciences company, has noted its strong support for TheraPsil, a nonprofit coalition that advocates for legal, Special Access Programme (“SAP”) access to psilocybin therapy for palliative care of Canadians. The coalition recently announced that Federal Minister of Health Patty Hajdu has approved the use psilocybin therapy in the end-of-life care … Continue reading “NetworkNewsBreaks — Cybin Calls Approval for Psilocybin Therapy in Palliative Care Treatment a ‘Watershed Moment’”
Cybin Corp., Canada’s premier mushroom life-sciences company focused on advancing psychedelic and nutraceutical-based products, looks to be at the right place at the right time during a shifting trend toward psilocybin. Highlighting this shift, TheraPsil, a non-profit coalition that advocates for legal, compassionate access to psilocybin therapy for palliative Canadians, recently shared news that four … Continue reading “NetworkNewsBreaks – Cybin Corp. Positioned in Shifting Trend Toward Psilocybin”
Cybin Corp. appears set for opportunity as new data increasingly finds promise in psychedelic medicines. As big pharma has failed to bring groundbreaking drug innovations into the mental-health space, psilocybin — the main compound of pharmaceutical psychedelic products — stands out, having shown positive results for the treatment of anxiety, depression, addiction, and eating and … Continue reading “NetworkNewsBreaks – Cybin Corp. to Deliver Psychedelic Medicines Targeting Conditions Failed by Big Pharma”
Psychedelics have shown positive results for treatment of mental health conditions including anxiety, depression, PTSD, addiction, eating disorders, ADHD Big pharma failed to bring drug innovations in mental health space; psychedelics may satisfy vast unmet need With secured delivery mechanisms and manufacturing contract in hand, Cybin appears well positioned to capitalize on growing market trend … Continue reading “Cybin Corp. Potentially Poised to be First Company Bringing Psychedelic Medicine to Treat Major Depressive Disorder”
Cybin Corp., a Canada-based, life-sciences company focused on the pharmaceutical development of psychedelic products as well as the functional mushroom market, looks to be in the right place at the right time. A mushrooming interest fuels this sector in an era where psychedelics, once a taboo substance, are being viewed in a powerful new light. … Continue reading “NetworkNewsBreaks – Cybin Corp. Advancing ‘Fungi-Derived’ Products Amid Mushrooming Interest in Psychedelics”
Clinical studies show serotonergic psychedelics may be effective in treating anxiety, depression, addiction and more Interest in serotonergic psychedelics has dramatically increased within last decade Cybin Corp. is focused on furthering research, development of psilocybin-based medications through Serenity Life Sciences Inc. For decades seen as a taboo substance, psychedelics today are being viewed in a … Continue reading “Cybin Corp. Emerging as Leader in Growing Psychedelics Space”
